Capricor Therapeutics to Present First Quarter 2022 Financial Results and Recent Corporate Update on May 10

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results for the first quarter ended March 31, 2022, after the market close on Tuesday, May 10, 2022. Management will then host a webcast and conference call at 4:30 p.m. ET on May 10.

Title: Capricor Therapeutics First Quarter 2022 Financial Results and Recent Corporate Update Conference Call and Webcast
Date: Tuesday, May 10, 2022
Time: 4:30 p.m. ET
Conference Call Details: Toll-Free: 888-256-1007
International: 929-477-0448
Conference ID: 3332017
Webcast: Webcast Link - Click Here

The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company’s website.

About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company focused on developing transformative cell and exosome-based therapeutics and vaccines for treating and preventing a broad spectrum of diseases. Capricor`s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in clinical development for treating Duchenne muscular dystrophy. Capricor is also developing its exosome technology as a next-generation therapeutic platform. The Company’s current focus is on developing exosomes capable of delivering nucleic acids, including mRNA as well as proteins, to treat or prevent a variety of diseases.